Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Receivables (2016 - 2025)

Cytosorbents' Change in Receivables history spans 15 years, with the latest figure at $137000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at $137000.0 for Q4 2025, down 87.44% from a year ago — trailing twelve months through Dec 2025 was -$423000.0 (down 124.59% YoY), and the annual figure for FY2025 was -$423000.0, down 124.59%.
  • Change in Receivables for Q4 2025 was $137000.0 at Cytosorbents, up from -$303000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.4 million in Q2 2023 to a low of -$1.3 million in Q3 2024.
  • The 5-year median for Change in Receivables is $53967.5 (2021), against an average of $120523.0.
  • The sharpest move saw Change in Receivables soared 752.71% in 2022, then plummeted 701.71% in 2023.
  • Year by year, Change in Receivables stood at -$698683.0 in 2021, then soared by 161.32% to $428400.0 in 2022, then tumbled by 183.49% to -$357670.0 in 2023, then soared by 405.03% to $1.1 million in 2024, then crashed by 87.44% to $137000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $137000.0, -$303000.0, and -$336889.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.